Evaluation of cardiovascular risk factors in patients with familial hypercholesterolemia from the North-Eastern area of Romania
Open Access
- 11 January 2021
- journal article
- research article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 20 (1) , 1-16
Abstract
Background: Familial hypercholesterolemia(FH) is one of the most frequent and important monogenic cholesterol pathologies. Traditional and non-traditional cardiovascular risk factors increase the prevalence of atherosclerotic cardiovascular disease(ASCVD) in this population. The aims of the study were: (a) to identify FH patients in the North-Eastern part of Romania and to analyze demographic, clinical and paraclinical data (b) to evaluate the risk of new cardiovascular events at follow-up in FH patients stratified by lipid-lowering agents. Methods: This first prospective study in the North-Eastern part of Romania was carried out between October 2017 and October 2019; out of 980 patients with dyslipidemia evaluated with the Dutch Lipid Network(DLCN) and Simon Broome(SM) scores, 61 patients with DLCN score above 3 and possible/probable FH(SM score) were included. Results: Nine hundred-eighty patients were examined and 61 (6.2%) were received the clinical diagnosis of FH. The mean age was 48.5±12.5 years, with more female patients than male patients (63.9% versus 36%). Hypertension was the main cardiovascular risk factor for both genders, followed by physical inactivity and obesity for the female group and active smoking for the male group. The measured DLCN score recorded: “possible” FH identified in 39.4%, “probable” FH in 45.9% and “definite” FH in 14.7%. The effective lipid-lowering drugs used were statin alone and statin in association with fenofibrate, which improved both the lipid profile values and the subclinical atherosclerosis markers (ankle-brachial index, carotid intima-media thickness and high-sensitivity C-reactive protein). New ASCVDs that emerged during the study were most commonly represented by coronary heart disease and stroke. At the same time, the new cardiovascular events were delayed in patients receiving the lipid-lowering drugs, without significant differences between them. Conclusions: In patients with suspected FH, the lipid-lowering agents during the follow-up period delayed the new cardiovascular events, yet failed to reach the goals proposed by the guidelines.Keywords
All Related Versions
Funding Information
- Ministry of Research and Innovation (PN-III-P4-ID-PCE-2016-0908)
This publication has 42 references indexed in Scilit:
- Peripheral arterial disease in heterozygous familial hypercholesterolemiaAtherosclerosis, 2015
- Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatmentEuropean Heart Journal, 2015
- C-Reactive Protein in Human Atherogenesis: Facts and FictionMediators of Inflammation, 2014
- Association of Peripheral Arterial and Cardiovascular Diseases in Familial HypercholesterolemiaArquivos Brasileiros de Cardiologia, 2014
- Effect of Lipid-Lowering Treatment on Natural History of Heterozygous Familial Hypercholesterolemia in Past Three DecadesThe American Journal of Cardiology, 2011
- Arterial endothelial function and wall thickness in familial hypercholesterolemia and familial combined hyperlipidemia and the effect of statins. A systematic review and meta-analysisAtherosclerosis, 2011
- Long-term LDL-c lowering in heterozygous familial hypercholesterolemia normalizes carotid intima-media thicknessAtherosclerosis, 2010
- Femoral Atherosclerosis In Heterozygous Familial HypercholesterolemiaArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trialThe Lancet, 2001
- Outcome of case finding among relatives of patients with known heterozygous familialBMJ, 2000